Podcasts about btcs

Toni Wahrstätter outlined the trade-offs of EIP-7928. The EF introduces the Trillion Dollar Security initiative. BTCS secures up to $58 million to buy ETH. And EigenDA V2 goes live on testnet. Read more: https://ethdaily.io/703 Disclaimer: Content is for informational purposes only, not endorsement or investment advice. The accuracy of information is not guaranteed.

In episode 95, we take a journey back to 1998 and revisit Before These Crowded Streets, the haunting, ambitious, and sonically rich album that redefined Dave Matthews Band. We break down the album track by track, exploring its musicianship, lyrics, and collaborations that made it a standout in DMB's catalog.  Join us as we unpack the lasting impact of BTCS—an album that continues to captivate fans over 25 years later. 

47e6GvjL4in5Zy5vVHMb9PQtGXQAcFvWSCQn2fuwDYZoZRk3oFjefr51WBNDGG9EjF1YDavg7pwGDFSAVWC5K42CBcLLv5U OR DONATE HERE: https://www.monerotalk.live/donate LINKS: https://x.com/AaronRDay TIMESTAMPS (00:00:00) Monerotopia Introduction. (00:15:27) Monerotopia Guest Segment w/ Aaron Day. (01:14:35) Monerotopia Price Report Segment w/ Bawdyanarchist. (02:01:08) Monerotopia News Segment w/ Tony. (02:01:35) ETH credit score (02:03:45) CBP ramps up ASIC miner crackdown with seizures. (02:04:45) Jack Maller and Dorsey talking about privacy coins. (02:06:12) El Salvador refusing BTC (02:07:23) Shopinbit report (02:08:00) US dollar back on a gold standard? (02:08:28) Monero upcoming updates (02:12:30) BTCs to ETFs (02:14:05) ROOMBA Vacuum exploited (02:17:05) Reuters paid by the feds (02:18:12) No Biometrics on Iphone. (02:20:53) JD Vance at the Munich conference. (02:24:31) Digital communism. (02:27:47) Monerotopia Viewers on Stage Segment. (03:25:15) Monerotopia Finalization. NEWS SEGMENT LINKS: JD Vance at the Munich conference: https://x.com/cryptotweetie/status/1890780627303076006?s=46&t=mVZ0A2C1bwwnAvgawJjlw PlanB transferred his BTC: https://x.com/vikrantnyc/status/1890779528848364014?s=46&t=mVZ0A2C1bwwnAvgawJjlw Shopinbit report: https://x.com/janowitz/status/1889611772245520531?s=46&t=mVZ0A2C1bwwnAvgawJjlw Iphone biometrics: https://x.com/creon/status/1888663088087658920?s=46&t=mVZ0A2C1bwwnAvgawJjlw Digital communism: https://x.com/7sees/status/1888610862916575587?s=46&t=mVZ0A2C1bwwnAvgawJjlw El Salvador refusing BTC: https://x.com/twopeopleinpara/status/1888659689983857044?s=46&t=mVZ0A2C1bwwnAvgawJjlw ETH credit score: https://x.com/cryptonator1337/status/1889067397380010423?s=46&t=mVZ0A2C1bwwnAvgawJjlw US dollar back on a gold standard?: https://x.com/adamemedia/status/1889562025816150145?s=46&t=mVZ0A2C1bwwnAvgawJjlw Jack Maller and Dorsey talking about privacy coins: https://x.com/alekceikozlov/status/1889899550892343466?s=46&t=mVZ0A2C1bwwnAvgawJjlw Reuters paid by the feds: https://x.com/elonmusk/status/1890182649974817070?s=46&t=mVZ0A2C1bwwnAvgawJjlw ROOMBA Vacuum exploited: https://x.com/xx17965797n/status/1890372808493924366?s=46&t=mVZ0A2C1bwwnAvgawJjlw ASICS seized: https://blockspace.media/insight/cbp-ramps-up-asic-miner-crackdown-with-seizures-new-import-holds/ Monero upcoming updates: https://www.reddit.com/r/Monero/s/53dkAfxVhk SPONSORS: PRICE REPORT: https://exolix.com/ GUEST SEGMENT: https://cakewallet.com & https://monero.com NEWS SEGMENT: https://www.wizardswap.io Don't forget to SUBSCRIBE! The more subscribers, the more we can help Monero grow! XMRtopia TELEGRAM: https://t.me/monerotopia XMRtopia MATRIX: https://matrix.to/#/%23monerotopia%3Amonero.social ODYSEE: https://bit.ly/3bMaFtE WEBSITE: monerotopia.com CONTACT: monerotopia@protonmail.com MASTADON: @Monerotopia@mastodon.social MONERO.TOWN https://monero.town/u/monerotopia Get Social with us: X: https://twitter.com/monerotopia INSTAGRAM: https://www.instagram.com/monerotopia DOUGLAS: https://twitter.com/douglastuman SUNITA: https://twitter.com/sunchakr TUX: https://twitter.com/tuxpizza

A daily update on what's happening in the Rocket Pool community on Discord, Twitter, Reddit, and the DAO forum. #RocketPool #rpl #Ethereum #eth #crypto #cryptocurrency #staking #news Podcast RSS: https://anchor.fm/s/cd29a3d8/podcast/rss Anchor.fm: https://anchor.fm/rocket-fuel Spotify: https://open.spotify.com/show/0Mvta9d2MsKq2u62w8RSoo Apple Podcasts: https://podcasts.apple.com/us/podcast/rocket-fuel/id1655014529 0:00 - Welcome Rocket Pool news 0:38 - Obol airdrop for RPers https://claim.obol.org/ https://x.com/Obol_Collective/status/1881719066685218818 BTCS running RP validators https://x.com/charles_btcs/status/1879535119834222974?s=46 https://www.btcs.com/wp-content/uploads/2025/01/Scaled-Validator-Implementation-PR-January-15-2025-vF2.pdf Exit arb in action https://discordapp.com/channels/405159462932971535/405163713063288832/1331019773097807872 Jasper talks to Trump team https://discord.com/channels/405159462932971535/998627604686979214/1330543231070375997 https://x.com/worldlibertyfi/status/1881457386671464804?s=46 https://etherscan.io/tx/0xf5f38c2394a3d1121b87e444a0c8f604d12359ea33a715433172f0fe63b1c52b NSSO stop selling rETH https://discord.com/channels/405159462932971535/405163713063288832/1330606728496156753 https://discord.com/channels/405159462932971535/405503016234385409/1331331113565556876 More contango incentives https://discord.com/channels/405159462932971535/405163713063288832/1329825934055833620 Liquify v2 date https://x.com/liquityprotocol/status/1881366913479328080?s=46 Boosted HAI rewards https://x.com/letsgethai/status/1879912357499207882 Rescue Node change in ownership https://x.com/Rescue_Node/status/1879952774970110114 AlphaGrowth's lost deals https://discord.com/channels/405159462932971535/1300824467076808776/1330992398180028556 DAO reports https://dao.rocketpool.net/t/pdao-2024-12-19-2025-01-16-treasury-report/3481 https://dao.rocketpool.net/t/imc-period-30-31-reports-period-31-32-budgets/3485 STAR application deadline passes https://dao.rocketpool.net/t/looking-for-overseer-for-the-star-initiative-reth-incubator/3475 Staking news Gas limit increase https://x.com/sassal0x/status/1879672562663514288 https://x.com/trent_vanepps/status/1879896778809786543? CSM going permissionless https://discord.com/channels/405159462932971535/405163713063288832/1329779113887535134 NodeSet rewards claiming soon https://discord.com/channels/968587363536220252/1153574664174579842/1329834713699057776 Ethereum news EF leadership discussion https://x.com/dannyryan/status/1879705279761178690? https://x.com/vitalikbuterin/status/1880635379771904423?s=46 https://x.com/VitalikButerin/status/1880637064158626267 https://x.com/vitalikbuterin/status/1881347052279349300?s=46 https://x.com/vitalikbuterin/status/1881298926650929415?s=46 https://x.com/vitalikbuterin/status/1881300872984166689?s=46 https://x.com/vitalikbuterin/status/1881350360381685816?s=46 https://x.com/dannyryan/status/1881742086703096313?s=46 https://x.com/vitalikbuterin/status/1881680518934384676?s=46 https://x.com/ethereumjoseph/status/1881721024057598309? Pectra timeline https://x.com/terencechain/status/1879892324353991052? https://x.com/nixorokish/status/1879893269028737138? https://x.com/terencechain/status/1879892324353991052 https://x.com/christine_dkim/status/1879919371684127176 In other news SEC Crypto Taskforce https://x.com/news_of_alpha/status/1881760567116829087? https://x.com/nategeraci/status/1881763205716025513?

Ein neuer Präsident, neue Kryptowährungen und neue Versprechungen. Bei Interesse und/oder für mehr Informationen zu meinem 2-Tägigen Finanzseminar (Frühjahr 2025), schreibe mir einfach eine kurze E-Mail an:  krapp@abatus-beratung.com Viel Spaß beim Hören,Dein Matthias Krapp(Transkript dieser Folge weiter unten) NEU!!! Hier kannst Du Dich kostenlos für meinen Minikurs registrieren und reinschauen. Es lohnt sich: https://portal.abatus-beratung.com/geldanlage-kurs/   

Conviértete en miembro de este canal para disfrutar de videos solo disponibles para miembros: https://www.youtube.com/channel/UC4DBbWZ3S16HxxgCLI5saAA/join *********************************************************************** #bitcoin #btc #etf Esto te puede interesar si quieres cambiar tu vida: - Enlace para suscribirte a la Newsletter de Crypto Mercados y Pymes: https://www.cryptomercadosypymes.com/ - Enlace para suscribirte a la Newsletter de PERITAJES TIC en la que vas a encontrar casos judiciales reales en los que un peritaje digital hace ganar el caso. Cuando lo leas te darás cuenta de que la realidad supera a la ficción: https://peritajestic.com/ - Escríbeme a este mail si la suscripción a la newsletter o la Masterclass te da problemas: cryptomercadosypymes@gmail.com *********************************************************************** Os dejo varios enlaces de afiliación: Un primer enlace a la web de la billetera fría Ledger: https://shop.ledger.com/?r=96c89dbd786b Este enlace de afiliados de Tradingview: https://es.tradingview.com/?aff_id=29244 Este enlace a servicios de dominios web y alojamiento de Webempresa: https://clientes.webempresa.com/europa/gestion/aff.php?aff=2121 *********************************************************************** Y este enlace de Amazon a varios libros muy recomendables: 1. "La filosofía de Bitcoin" de Álvaro D. María: https://amzn.to/3KiB5EE 2. ·"Imbatible. La fórmula para alcanzar la libertad financiera" de Tony Robbins: https://amzn.to/3yA003K 3. "Ten peor coche que tu vecino" de Luis Pita: https://amzn.to/3R2nQeR 4. "El sutil arte de que (casi todo) te importe una mi@rda" de Mark Manson : https://amzn.to/45aE4HZ 5. "La psicología del dinero. Cómo piensan los ricos". Morgan Housel: https://amzn.to/3WYj7Pi 6. "La medusa inmortal. Todo lo que hay que saber para vivir más años" de Nicklas Brendborg: https://amzn.to/4aDktSB 7. "El futuro de la humanidad". Michiu Kaku: https://amzn.to/3ysIPB2 *********************************************************************** Disclaimer: este video y su contenido son solo para fines informativos y no constituyen una oferta de venta o intercambio, una solicitud de compra o recomendación de ningún valor, criptomoneda o producto relacionado, ni constituye una oferta para proporcionar inversión asesoramiento u otros servicios relacionados por parte de Crypto Mercados y Pymes. Crypto Mercados y Pymes puede tener una inversión financiera con las criptomonedas discutidas en este video. Al preparar este video, NO se han tenido en cuenta las necesidades financieras o de inversión individuales del espectador ni se ofrece ningún consejo financiero o de inversión. Todas las opiniones expresadas en este video se prepararon en función de la información disponible en el momento en que se escribieron y/o publicaron dichas opiniones. Información modificada o adicional podría hacer que tales opiniones cambien. *********************************************************************** Crypto Mercados y Pymes, el mejor canal online sobre mercados financieros y criptomonedas: #bitcoin #cryptocurrency #news #btc #ethereum #eth #cryptocurrency #litecoin #altcoin #altcoins #forex #money #best #trading #bitcoinmining #invest #trader #cryptocurrencies #top #investing #entrepreneur #business #success #investment #finance #motivation #coinbase #stocks #wallstreet #investor #wealth #bullish #bearish #cryptolive #altcoindaily *********************************************************************** cryptocurrency, crypto, altcoin, altcoin daily, news, best investment, top altcoins, las mejores altcoins, ripple, la mejor inversion en cripto, best crypto investment, ethereum, xrp, crash, bottom, suelo, crash, price, precio, predicción, prediction, podcast, interview, entrevista,finanzas,finance, stock, investment, inversión, too late, demasiado tarde, bitcoin, cryptocurrency news, noticias de criptomonedas, bitcoin news, noticias de bitcoin, cryptocurrency news media online, noticias de criptomonedas online, defi, finanzas descentralizadas, ¿debería comprar bitcoin?, ¿debería comprar Ethereum?, bitcoin una buena inversión, la mejor inversión cripto, ethereum una buena inversión, ethereum a good investment, best crypto investments, predicción 2024, 2024 prediction, nfts, los mejores ntfs, best nfts, ¿debería comprar cardano?, should I buy cardano?, coin bureau, binance, coinbase, coffeezilla,

Bienvenido a Entorno Blockchain Podcast

Conviértete en miembro de este canal para disfrutar de videos solo disponibles para miembros: https://www.youtube.com/channel/UC4DBbWZ3S16HxxgCLI5saAA/join *********************************************************************** #bitcoin #btc #etf Esto te puede interesar si quieres cambiar tu vida: - Enlace a la Masterclass CARTERA METAMASK: https://www.cryptomercadosypymes.com/landing-metamask/ - Enlace para suscribirte a la Newsletter de Crypto Mercados y Pymes: https://www.cryptomercadosypymes.com/ - Enlace para suscribirte a la Newsletter de PERITAJES TIC en la que vas a encontrar casos judiciales reales en los que un peritaje digital hace ganar el caso. Cuando lo leas te darás cuenta de que la realidad supera a la ficción: https://peritajestic.com/ - Escríbeme a este mail si la suscripción a la newsletter o la Masterclass te da problemas: cryptomercadosypymes@gmail.com *********************************************************************** Os dejo varios enlaces de afiliación: Un primer enlace a la web de la billetera fría Ledger: https://shop.ledger.com/?r=96c89dbd786b Este enlace de afiliados de Tradingview: https://es.tradingview.com/?aff_id=29244 Este enlace a servicios de dominios web y alojamiento de Webempresa: https://clientes.webempresa.com/europa/gestion/aff.php?aff=2121 *********************************************************************** Y este enlace de Amazon a varios libros muy recomendables: 1. "La filosofía de Bitcoin" de Álvaro D. María: https://amzn.to/3KiB5EE 2. ·"Imbatible. La fórmula para alcanzar la libertad financiera" de Tony Robbins: https://amzn.to/3yA003K 3. "Ten peor coche que tu vecino" de Luis Pita: https://amzn.to/3R2nQeR 4. "El sutil arte de que (casi todo) te importe una mi@rda" de Mark Manson : https://amzn.to/45aE4HZ 5. "La psicología del dinero. Cómo piensan los ricos". Morgan Housel: https://amzn.to/3WYj7Pi 6. "La medusa inmortal. Todo lo que hay que saber para vivir más años" de Nicklas Brendborg: https://amzn.to/4aDktSB 7. "El futuro de la humanidad". Michiu Kaku: https://amzn.to/3ysIPB2 *********************************************************************** Disclaimer: este video y su contenido son solo para fines informativos y no constituyen una oferta de venta o intercambio, una solicitud de compra o recomendación de ningún valor, criptomoneda o producto relacionado, ni constituye una oferta para proporcionar inversión asesoramiento u otros servicios relacionados por parte de Crypto Mercados y Pymes. Crypto Mercados y Pymes puede tener una inversión financiera con las criptomonedas discutidas en este video. Al preparar este video, NO se han tenido en cuenta las necesidades financieras o de inversión individuales del espectador ni se ofrece ningún consejo financiero o de inversión. Todas las opiniones expresadas en este video se prepararon en función de la información disponible en el momento en que se escribieron y/o publicaron dichas opiniones. Información modificada o adicional podría hacer que tales opiniones cambien. *********************************************************************** Crypto Mercados y Pymes, el mejor canal online sobre mercados financieros y criptomonedas: #bitcoin #cryptocurrency #news #btc #ethereum #eth #cryptocurrency #litecoin #altcoin #altcoins #forex #money #best #trading #bitcoinmining #invest #trader #cryptocurrencies #top #investing #entrepreneur #business #success #investment #finance #motivation #coinbase #stocks #wallstreet #investor #wealth #bullish #bearish #cryptolive #altcoindaily *********************************************************************** cryptocurrency, crypto, altcoin, altcoin daily, news, best investment, top altcoins, las mejores altcoins, ripple, la mejor inversion en cripto, best crypto investment, ethereum, xrp, crash, bottom, suelo, crash, price, precio, predicción, prediction, podcast, interview, entrevista,finanzas,finance, stock, investment, inversión, too late, demasiado tarde, bitcoin, cryptocurrency news, noticias de criptomonedas, bitcoin news, noticias de bitcoin, cryptocurrency news media online, noticias de criptomonedas online, defi, finanzas descentralizadas, ¿debería comprar bitcoin?, ¿debería comprar Ethereum?, bitcoin una buena inversión, la mejor inversión cripto, ethereum una buena inversión, ethereum a good investment, best crypto investments, predicción 2024, 2024 prediction, nfts, los mejores ntfs, best nfts, ¿debería comprar cardano?, should I buy cardano?, coin bureau, binance, coinbase, coffeezilla,

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! Conviértete en miembro de este canal para disfrutar de videos solo disponibles para miembros: https://www.youtube.com/channel/UC4DBbWZ3S16HxxgCLI5saAA/join *********************************************************************** #bitcoin #btc #etf Esto te puede interesar si quieres cambiar tu vida: - Enlace a la Masterclass CARTERA LAST CALL: https://www.cryptomercadosypymes.com/landing-cartera-last-call/ - Enlace para suscribirte a la Newsletter de Crypto Mercados y Pymes: https://www.cryptomercadosypymes.com/ - Enlace para suscribirte a la Newsletter de PERITAJES TIC en la que vas a encontrar casos judiciales reales en los que un peritaje digital hace ganar el caso. Cuando lo leas te darás cuenta de que la realidad supera a la ficción: https://peritajestic.com/ - Escríbeme a este mail si la suscripción a la newsletter o la Masterclass te da problemas: cryptomercadosypymes@gmail.com *********************************************************************** Os dejo varios enlaces de afiliación: Un primer enlace a la web de la billetera fría Ledger: https://shop.ledger.com/?r=96c89dbd786b Este enlace de afiliados de Tradingview: https://es.tradingview.com/?aff_id=29244 Este enlace a servicios de dominios web y alojamiento de Webempresa: https://clientes.webempresa.com/europa/gestion/aff.php?aff=2121 *********************************************************************** Y este enlace de Amazon a varios libros muy recomendables: 1. "La filosofía de Bitcoin" de Álvaro D. María: https://amzn.to/3KiB5EE 2. ·"Imbatible. La fórmula para alcanzar la libertad financiera" de Tony Robbins: https://amzn.to/3yA003K 3. "Ten peor coche que tu vecino" de Luis Pita: https://amzn.to/3R2nQeR 4. "El sutil arte de que (casi todo) te importe una mi@rda" de Mark Manson : https://amzn.to/45aE4HZ 5. "La psicología del dinero. Cómo piensan los ricos". Morgan Housel: https://amzn.to/3WYj7Pi 6. "La medusa inmortal. Todo lo que hay que saber para vivir más años" de Nicklas Brendborg: https://amzn.to/4aDktSB 7. "El futuro de la humanidad". Michiu Kaku: https://amzn.to/3ysIPB2 *********************************************************************** Disclaimer: este video y su contenido son solo para fines informativos y no constituyen una oferta de venta o intercambio, una solicitud de compra o recomendación de ningún valor, criptomoneda o producto relacionado, ni constituye una oferta para proporcionar inversión asesoramiento u otros servicios relacionados por parte de Crypto Mercados y Pymes. Crypto Mercados y Pymes puede tener una inversión financiera con las criptomonedas discutidas en este video. Al preparar este video, NO se han tenido en cuenta las necesidades financieras o de inversión individuales del espectador ni se ofrece ningún consejo financiero o de inversión. Todas las opiniones expresadas en este video se prepararon en función de la información disponible en el momento en que se escribieron y/o publicaron dichas opiniones. Información modificada o adicional podría hacer que tales opiniones cambien. *********************************************************************** Crypto Mercados y Pymes, el mejor canal online sobre mercados financieros y criptomonedas: #bitcoin #cryptocurrency #news #btc #ethereum #eth #cryptocurrency #litecoin #altcoin #altcoins #forex #money #best #trading #bitcoinmining #invest #trader #cryptocurrencies #top #investing #entrepreneur #business #success #investment #finance #motivation #coinbase #stocks #wallstreet #investor #wealth #bullish #bearish #cryptolive #altcoindaily *********************************************************************** cryptocurrency, crypto, altcoin, altcoin daily, news, best investment, top altcoins, las mejores altcoins, ripple, la mejor inversion en cripto, best crypto investment, ethereum, xrp, crash, bottom, suelo, crash, price, precio, predicción, prediction, podcast, interview, entrevista,finanzas,finance, stock, investment, inversión, too late, demasiado tarde, bitcoin, cryptocurrency news, noticias de criptomonedas, bitcoin news, noticias de bitcoin, cryptocurrency news media online, noticias de criptomonedas online, defi, finanzas descentralizadas, ¿debería comprar bitcoin?, ¿debería comprar Ethereum?, bitcoin una buena inversión, la mejor inversión cripto, ethereum una buena inversión, ethereum a good investment, best crypto investments, predicción 2024, 2024 prediction, nfts, los mejores ntfs, best nfts, ¿debería comprar cardano?, should I buy cardano?, coin bureau, binance, coinbase, coffeezilla,Escucha este episodio completo y accede a todo el contenido exclusivo de Crypto Mercados y Pymes. Descubre antes que nadie los nuevos episodios, y participa en la comunidad exclusiva de oyentes en https://go.ivoox.com/sq/1336498

ANNETTE TUDOR BTCS DIRECTOR OF SCHOOLS JULY 23See omnystudio.com/listener for privacy information.

00:00 - No episódio de hoje... 01:54 - EUA com problemas, ainda comprar dólar e ativos? 08:54 - Alteração do mandato no BC por Lula: risco? 09:37 - Lula influencia dólar? Setores beneficiados com câmbio alto? 12:56 - Bacen acertou ao não intervir no dólar? 13:25 - Confiança dos investidores nas declarações de Lula e Haddad? 15:37 - Risco de política de empréstimos baixos após saída do RCN? 16:29 - Blocos econômicos são viáveis ou utopia capitalista? 18:19 - Reserva de 350 bi pode cobrir dívida crescente de 200 bi/ano? 19:03 - Chance de taxação de Fiis e Fiagro? 19:50 - Setor resistente à inflação? 21:43 - Governo gasta mais, Bacen aumenta passivo? 23:44 - BTCs em CEX são arriscados em crash mundial? 24:41 - Juros antigos ainda afetam inflação? 27:21 - Trump e impostos: agravamento fiscal dos EUA? 29:47 - Êxodo de milionários no Reino Unido: soluções para crescimento? 31:33 - Próxima temporada do Nas Fronteiras do Dinheiro? O "Ulrich Responde" é uma série de vídeos em que respondo perguntas enviadas por membros do canal e seguidores onde abordo diversos tópicos relacionados à economia, finanças e investimentos Nesse formato de vídeo falamos sobre política econômica, inflação, taxas de juros, até investimentos em criptomoedas e ações, oferecendo uma análise aprofundada e bem fundamentada em cada episódio, trazendo informação para quem busca entender melhor a economia e tomar decisões financeiras mais informadas

Featuring perspectives from Ms Blanca Ledezma, Dr Stacey Stein, Ms Amanda K Wagner and Dr Mark Yarchoan, including the following topics: Introduction (0:00) Adjuvant Therapy for Early-Stage Hepatocellular Carcinoma (HCC) (9:40) Role of Immunotherapy in Intermediate-Stage HCC (17:02) First-Line Therapy for Advanced HCC (19:56) Immunotherapy in the Management of Advanced Biliary Tract Cancers (BTCs) (44:29) Biomarker Testing Recommendations and the Use of FGFR Inhibitors for Advanced Cholangiocarcinoma (58:02) Potential Role of HER2-Targeted Therapy for BTCs (1:17:16) CME information and select publications  

It was an absolute honor having DMB & music industry legend Steve Lillywhite join us live from "The Lillipad" for Convos on the Corner! This has truly been years in the making and because he has been a part of many interviews in his career, we wanted to make this one as fresh and unique as possible.  In Part 1, we dive into how Steve got his start in music, what he's up to these days, and touch on some of the other bands he has worked with including The Rolling Stones, Phish, Peter Gabriel, Talking Heads, and of course U2 who he recently joined in Vegas to help prepare for their residency at The Sphere. We also discussed his incredible work with DMB on UTTAD, Crash, BTCS and the Lillywhite Sessions. Oh, and we actually had Steve listen to infamous MacHead and give us his reaction to hearing it again after all of these years, what it needed to have in order to have made the album, and the story behind its "lyrics". We hope you enjoy this enlightening convo with Steve - and be sure to come back next week for Part 2 where we discuss his works with Phish, the current band he'd want to produce, and an extended discussion about his potential final DMB record, Away From the World. 

By Selva Ozelli. Author of Sustainably Investing in Digital Assets Globally The veil on the identity of Satoshi Nakamoto, the author of Bitcoin's White Paper that proposed the blockchain-based decentralized crypto currency, still has not been lifted. This "'identity issue,' namely whether Dr. Craig Wright is the pseudonymous 'Satoshi Nakamoto,' i.e., the person who created Bitcoin in 2009" or not according to high court judge John Mellor is still being litigated in the UK with the support of Bitcoin Legal Defense Fund set up by Block CEO Jack Dorsey. Is Dr. Craig Wright Satoshi Nakamoto? "The Bitcoin Legal Defense Fund is a nonprofit entity that aims to minimize legal headaches that discourage software developers from actively developing Bitcoin and related projects such as the Lightning Network, Bitcoin privacy protocols, and the like," explained Jack. Unfortunately, the self-proclaimed inventor of Bitcoin, Dr. Craig Wright is only one of many to claim to be Satoshi Nakamoto according to an article "The Faketoshi" authored by Arthur van Pelt. Adding layers to Satoshi's identity mystery is a Binance wallet sending approximately $1.2 million worth of BTCs to Satoshi's genesis wallet on January 5, 2024, two days after BTC's 15th Birthday. The mist around Dr. Craig's 'identity issue' is expected to lift "By 4 pm on January 18, 2024, [when] Dr Wright and COPA shall exchange and shall serve on the Developer Defendants expert reports on (a) forensic document analysis in respect of the Additional Documents,- [95 documents dating back to 2007] - stored on the Samsung Drive, and the BDO Drive; and (b) LaTeX software," Mellor added. Once the identity of Satoshi is known, if this person is a US person with an estimated BTC wealth of $41B the US taxpayer is expected to file Form 8300 with the IRS by January 20, 2024 for the $1.2M in BTC received since effective January 1 2024, any crypto transaction over $10,000 must be electronically (if they are required to file certain other information returns electronically) reported. Noncompliance with Form 8300 subject's taxpayer to civil and criminal penalties. Bad Actors Out of the Way While the "real" author of the Bitcoin White Paper continues to being debated in the UK court system, the Digital Asset industry went through a cleansing of bad actors in the US during 2023. The world's largest Digital Asset Exchange Binance and its CEO pleaded guilty to federal charges and agreed to pay over $4B to resolve the Justice Department's investigation into violations related to the Bank Secrecy Act, failure to register as a money transmitting business, and the International Emergency Economic Powers Act (IEEPA). See: https://crypto.news/binance-founder-and-ceo-plead-guilty-to-federal-charges-opinion/ Binance, Coinbase, Terraform Labs and others also faced action by the SEC for operating unregistered securities exchanges which are ongoing. "In 2023, the U.S. experienced significant regulatory shifts, particularly in response to the FTX collapse which was followed by five crypto-friendly bank failures. The Biden administration's 'regulation by enforcement' strategy shaped the federal landscape, spearheaded by Gary Gensler and the SEC. Amidst this, states like Colorado stood out as beacons for the crypto industry, accounting for 33% of all U.S. crypto businesses. This success is primarily attributed to forward-thinking measures such as Colorado's 'Digital Token Act' and key initiatives like ETH Denver, all nurtured under Governor Jared Polis' vision" explained Sergiu Hamza, CEO of Coincub which prepared Reports on US MSB and global VASPs . North American investors, money managers and even CBOE Digital president John Palmer is confident that a new wave of institutional and pension fund investment will follow spot Bitcoin ETF approvals. Already several spot BTC exchange-traded fund (ETF) applicants Vaneck, Valkyrie, Grayscale Investments Fidelity BlackRock, and Bitwise filed to register their funds as secu...

Entorno Blockchain es el podcast donde vas a entender más allá de la especulación -NO ES RECOMENDACIÓN DE INVERSIÓN, TÚ ERES RESPONSABLE DE TUS DECISIONES Y SACAR TUS PROPIAS CONCLUSIONES. ⁠Compra BTC en Binance aquí.⁠ El Halving es un fenómeno natural de Bitcoin, donde desde el día 1 está programado que la creación de nuevos BTCs que se da con cada bloque minado (10 minutos aprox), hace que cada 210,000 bloques (4 años aprox) se reduzca a la mitad. ¿Qué pasa con el precio de un activo cuando su oferta disminuye y la demanda no solo no se mantiene constante, sino que crece? Adivínalo ;). Sígueme en Instagram como ⁠Berpu.eth⁠ Episodio grabado por Miguel Bernal Pueblita, Blockchain Certified Expert por la European Tech School y Master en Blockchain por Nuclio School.

While the band has been on a much deserved break, so have we, but as some of the DMB family hit the road again, so did we. Nolan was lucky enough to catch Tim Reynolds and Joe Lawlor in Raleigh, NC last week as TR3 kicked off their fall tour in style. We recap this special night and highlight how incredible it is to be up close and personal with these true musical virtuosos. We also finally give our opinions surrounding the good and bad surrounding the BTCS 25th anniversary re-release and related merch. It's good to be back and we hope you all enjoy!

In today's EMERGENCY EPISODE; Jeanette, Trisha, Matt, and Shawn discuss the announcement of the long awaited 25th anniversary BTCS vinyl.

As all of you are well aware, Reliability Matters is all about reliability, specifically reliability of circuit assemblies. One challenge that seems to be persistent within our space is design for manufacturability, or DfM. If you're a contract manufacturer, no doubt you've had the experience of being asked to build a product that seems unbuildable. One example that rings true was the introduction of bottom terminated components or BTCs. BTC's are marvelous components. Because all the lead terminations are below the part, they permit highly dense component placement and highly miniaturized assemblies. They also presented a number of unique challenges in reflow, in many cases voiding, cleaning, and inspection. Like many other industries, we are not immune to the introduction of new technologies that may lack implementation knowledge. We then spend the next several years at technical conferences and symposiums learning us how to implement these new technologies. There are many acronyms in our industry that begin with Df…  Design for testability, mechanical assembly, serviceability, reliability, and so many more. So many in fact, that there is a placeholder acronym for all of the various design fours refer to as DFx. Perhaps the holy grail of DFx is DfM (design for manufacturability) as it encompasses so many aspects of assembly. Today Andrew Williams helps us understand what exactly DFM is. He is engineering manager for electronics manufacturing at PRIDE Industries. He has more than 30 years of experience in manufacturing and design and holds an SMT Process Engineer certification from SMTA and an IPC Certified Electronics Program Manager. He is a guest lecturer at UC Davis and Cal State University Sacramento for Supply Chain Management, Operations, and TQM courses, and speaks frequently on DfM, DfS, and other DfX topics.

This week, our Special Guest, Brian Foster takes the lead, exploring the significance of the recent ETF applications, Coinbase's role in this space, and explains the surveillance sharing aspect. He dives into why now is an opportune time for ETFs and discusses their relation to other ways of accessing bitcoin and crypto, including Coinbase's own retail business.Josh provides a market update, covering the biggest movers and the latest trends in NFT floors. He also discusses BTCs positive dynamics, the Binance.US discount, DCG-related news, and developments in the Polygon and Arbitrum ecosystems.David covers important upcoming economic indicators such as CPI, PPI, and earnings reports from notable institutions like JPM and Citi. He also runs through the Cancun upgrade roadmap and the recent progress of L2 scaling solutions.Greg analyzes flows and volatility, sharing insights on BTC and ETH basis. He also discusses the recent trends in the Bored Ape NFT market.Sid addresses recent multichain hacks, providing analysis and insights into their impact on the crypto landscape and looks forward to EthCC in Paris next week.Please, don't forget to like and subscribe so others can benefit from the team's great content!HostBen Floyd, Head of Execution ServicesSpecial GuestBrian Foster, Director Americas Institutional SalesPresentersJoshua Pak, CES SalestraderDavid Duong, Head of Institutional ResearchGreg Sutton, Senior CES SalestraderSid Shekar, Engineering ManagerLink to Research and Insights Hubhttps://www.coinbase.com/institutional/research-insights

Featuring perspectives from Dr Anthony El-Khoueiry, Dr Robin K (Katie) Kelley and Prof Arndt Vogel, includingthe following topics: Hepatocellular Carcinoma (HCC) Introduction (0:00) Adjuvant therapy for HCC (1:47) First-line systemic therapy for advanced/metastatic HCC (10:36) Management of HCC in the second-line setting and beyond (18:27) Biliary Tract Cancers (BTCs) First-line systemic therapy for metastatic BTCs (26:41) Management of metastatic cholangiocarcinoma with FGFR fusions/rearrangements (35:16) Management of metastatic cholangiocarcinoma with IDH1 mutations  (43:54) Management of metastatic HER2-positive BTC (48:47) CME information and select publications

Featuring perspectives from Drs Eric Lee, Neil Morganstein and Swati Vishwanathan, including the following topics: •      Gastroesophageal Cancers — Zev Wainberg, MD, MSc  o   Introduction (0:00) o   Systemic therapy considerations for HER2-negative localized gastroesophageal cancers (4:33) o   First-line systemic therapy for metastatic esophageal or gastric cancer (10:05) o   Zolbetuximab/chemotherapy as first-line treatment for HER2-negative, locally advanced unresectable or metastatic gastric and gastroesophageal junction cancers (16:19) o   Repeat tissue biopsy versus circulating tumor DNA testing for HER2-positive GI cancers after disease progression on first-line therapy (20:59) o   Trastuzumab deruxtecan as second-line therapy for HER2-positive gastric cancer; management of CNS disease (25:05) •      Hepatobiliary Cancers — Lipika Goyal, MD, MPhil  o   Tissue biopsy for suspected hepatocellular carcinoma (HCC) (29:59) o   Atezolizumab/bevacizumab versus durvalumab/tremelimumab as first-line therapy for HCC; disease etiology and response to treatment (33:34) o   Liver-directed therapy in the era of effective novel systemic regimens (40:50) o   First-line, single-agent immunotherapy for HCC (44:33) o   Sequencing tyrosine kinase inhibitors for patients with HCC with and without contraindications to immunotherapy (47:46) o   Survival benefit with durvalumab/gemcitabine/cisplatin for advanced biliary tract cancers (BTCs) in the TOPAZ-1 trial — A new standard? (51:25) o   Spectrum of targetable genetic alterations in BTCs; novel FGFR2 inhibitors for cholangiocarcinoma (54:28) CME information and select publications

Insider Financial discusses the recent volatility in bank stocks, bond yields, tech stocks, Bitcoin, and gold. To get our FREE reports and eBook, go to: https://signup.insiderfinancial.com/ To get FREE stocks and trade from 4am to 8pm on WeBull, go to: https://a.webull.com/i/insiderfinancial This video covers TLT, BTC, GLD, USO, QQQ, SPY, FRC, SI, SIVB, NVDA, AMD, BXP, SLG, VNO, GME, BKKT, HIVE, BTCS, RIOT, MARA. Trading Plan For This Week Disclosure: Insider Financial has not been compensated for this video. Insider Financial is not an investment advisor; this video does not provide investment advice. Always do your own research, make your own investment decisions, or consult with your nearest financial advisor. This video is not a solicitation or recommendation to buy, sell, or hold securities. This video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance. For more information, please read our full disclaimer: https://insiderfinancial.com/disclaimer/ SPY, TLT, Bitcoin, BTC, crypto, GLD, USO, QQQ, FRC stock, SI stock, SIVB stock, NVDA stock, AMD stock, BXP stock, SLG stock, VNO stock, GME stock, Gamestop stock, BKKT stock, HIVE stock, BTCS stock, RIOT stock, MARA stock, small caps, trading, otc stocks, otc stocks list, penny stocks, penny stocks list, NASDAQ penny stocks, NYSE stocks, NYSE penny stocks #pennystocks #stockmarketnews #tradingstrategy

Go online to PeerView.com/FKB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science continues to support a diverse management model for advanced biliary tract cancers (BTCs), including immune-based and targeted platforms, culminating to the first meaningful advancements in frontline therapy for advanced/metastatic BTC in over a decade. Collectively these clinical trends have expanded the use of individualized management strategies, leading to enhanced clinical outcomes for patients with advanced BTC. In this activity, based on a recent live symposium, expert panelists provide data and practical guidance on the current status of care in BTC and new developments related to the use of novel and emerging immunotherapies and targeted options (eg, PD-1 and PD-L1 inhibitors, FGFR, IDH, TRK, and HER2-directed agents). Case presentations explore next-generation care for today's patients with BTC using personalized upfront and sequential treatment management models. Don't miss this chance to get personal with advanced BTC! Upon completion of this activity, participants should be better able to: Summarize the latest clinical evidence supporting the use of immunotherapy and targeted platforms for patients with advanced BTCs; Develop personalized management plans for patients with advanced BTCs based on up-to-date clinical evidence on novel immunotherapeutic and targeted approaches, expert recommendations, comorbidities, and other factors at baseline; and Manage unique safety considerations associated with the use of novel targeted and immunotherapy options for BTCs

Go online to PeerView.com/FKB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science continues to support a diverse management model for advanced biliary tract cancers (BTCs), including immune-based and targeted platforms, culminating to the first meaningful advancements in frontline therapy for advanced/metastatic BTC in over a decade. Collectively these clinical trends have expanded the use of individualized management strategies, leading to enhanced clinical outcomes for patients with advanced BTC. In this activity, based on a recent live symposium, expert panelists provide data and practical guidance on the current status of care in BTC and new developments related to the use of novel and emerging immunotherapies and targeted options (eg, PD-1 and PD-L1 inhibitors, FGFR, IDH, TRK, and HER2-directed agents). Case presentations explore next-generation care for today's patients with BTC using personalized upfront and sequential treatment management models. Don't miss this chance to get personal with advanced BTC! Upon completion of this activity, participants should be better able to: Summarize the latest clinical evidence supporting the use of immunotherapy and targeted platforms for patients with advanced BTCs; Develop personalized management plans for patients with advanced BTCs based on up-to-date clinical evidence on novel immunotherapeutic and targeted approaches, expert recommendations, comorbidities, and other factors at baseline; and Manage unique safety considerations associated with the use of novel targeted and immunotherapy options for BTCs

Go online to PeerView.com/FKB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science continues to support a diverse management model for advanced biliary tract cancers (BTCs), including immune-based and targeted platforms, culminating to the first meaningful advancements in frontline therapy for advanced/metastatic BTC in over a decade. Collectively these clinical trends have expanded the use of individualized management strategies, leading to enhanced clinical outcomes for patients with advanced BTC. In this activity, based on a recent live symposium, expert panelists provide data and practical guidance on the current status of care in BTC and new developments related to the use of novel and emerging immunotherapies and targeted options (eg, PD-1 and PD-L1 inhibitors, FGFR, IDH, TRK, and HER2-directed agents). Case presentations explore next-generation care for today's patients with BTC using personalized upfront and sequential treatment management models. Don't miss this chance to get personal with advanced BTC! Upon completion of this activity, participants should be better able to: Summarize the latest clinical evidence supporting the use of immunotherapy and targeted platforms for patients with advanced BTCs; Develop personalized management plans for patients with advanced BTCs based on up-to-date clinical evidence on novel immunotherapeutic and targeted approaches, expert recommendations, comorbidities, and other factors at baseline; and Manage unique safety considerations associated with the use of novel targeted and immunotherapy options for BTCs

Go online to PeerView.com/FKB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science continues to support a diverse management model for advanced biliary tract cancers (BTCs), including immune-based and targeted platforms, culminating to the first meaningful advancements in frontline therapy for advanced/metastatic BTC in over a decade. Collectively these clinical trends have expanded the use of individualized management strategies, leading to enhanced clinical outcomes for patients with advanced BTC. In this activity, based on a recent live symposium, expert panelists provide data and practical guidance on the current status of care in BTC and new developments related to the use of novel and emerging immunotherapies and targeted options (eg, PD-1 and PD-L1 inhibitors, FGFR, IDH, TRK, and HER2-directed agents). Case presentations explore next-generation care for today's patients with BTC using personalized upfront and sequential treatment management models. Don't miss this chance to get personal with advanced BTC! Upon completion of this activity, participants should be better able to: Summarize the latest clinical evidence supporting the use of immunotherapy and targeted platforms for patients with advanced BTCs; Develop personalized management plans for patients with advanced BTCs based on up-to-date clinical evidence on novel immunotherapeutic and targeted approaches, expert recommendations, comorbidities, and other factors at baseline; and Manage unique safety considerations associated with the use of novel targeted and immunotherapy options for BTCs

Go online to PeerView.com/FKB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science continues to support a diverse management model for advanced biliary tract cancers (BTCs), including immune-based and targeted platforms, culminating to the first meaningful advancements in frontline therapy for advanced/metastatic BTC in over a decade. Collectively these clinical trends have expanded the use of individualized management strategies, leading to enhanced clinical outcomes for patients with advanced BTC. In this activity, based on a recent live symposium, expert panelists provide data and practical guidance on the current status of care in BTC and new developments related to the use of novel and emerging immunotherapies and targeted options (eg, PD-1 and PD-L1 inhibitors, FGFR, IDH, TRK, and HER2-directed agents). Case presentations explore next-generation care for today's patients with BTC using personalized upfront and sequential treatment management models. Don't miss this chance to get personal with advanced BTC! Upon completion of this activity, participants should be better able to: Summarize the latest clinical evidence supporting the use of immunotherapy and targeted platforms for patients with advanced BTCs; Develop personalized management plans for patients with advanced BTCs based on up-to-date clinical evidence on novel immunotherapeutic and targeted approaches, expert recommendations, comorbidities, and other factors at baseline; and Manage unique safety considerations associated with the use of novel targeted and immunotherapy options for BTCs

Go online to PeerView.com/FKB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science continues to support a diverse management model for advanced biliary tract cancers (BTCs), including immune-based and targeted platforms, culminating to the first meaningful advancements in frontline therapy for advanced/metastatic BTC in over a decade. Collectively these clinical trends have expanded the use of individualized management strategies, leading to enhanced clinical outcomes for patients with advanced BTC. In this activity, based on a recent live symposium, expert panelists provide data and practical guidance on the current status of care in BTC and new developments related to the use of novel and emerging immunotherapies and targeted options (eg, PD-1 and PD-L1 inhibitors, FGFR, IDH, TRK, and HER2-directed agents). Case presentations explore next-generation care for today's patients with BTC using personalized upfront and sequential treatment management models. Don't miss this chance to get personal with advanced BTC! Upon completion of this activity, participants should be better able to: Summarize the latest clinical evidence supporting the use of immunotherapy and targeted platforms for patients with advanced BTCs; Develop personalized management plans for patients with advanced BTCs based on up-to-date clinical evidence on novel immunotherapeutic and targeted approaches, expert recommendations, comorbidities, and other factors at baseline; and Manage unique safety considerations associated with the use of novel targeted and immunotherapy options for BTCs

On todays show I do live TA on Bitcoin and the rest of the crypto currency market. As Bitcoin has shown a bit of volatility today I will let you know what I think BTCs next move will be. We will be taking a look at the key levels you need to be watching for your next trades and where I will be expecting some strong resistance. At the end of the stream we will be spinning the wheel of pain and pleasure where you will have the chance to win some free crypto! Join Bitget NOW for an exchange that puts users first! ➡️ https://partner.bitget.com/bg/FrankieCandles Join my PREMIUM Discord! ➡️ https://mee6.gg/m/frankiecandlespremium Join My FREE Discord! ➡️ https://discord.gg/FrankieCandles Do you like the custom indicators? Get them here! ➡️ https://bitlabacademy.com/ref/FrankieCandles/

O desenvolvedor Luke Dashjr, colaborador há muitos anos do Bitcoin Core, anunciou no dia 1 de janeiro de 2023 que sua chave PGP teria sido comprometida e, junto com ela, centenas de BTCs teriam sido roubados. Esse anúncio, sem detalhes, gerou algumas repercussões interessantes que achei importantes comentar a respeito. Será que é impossível fazer segurança de Bitcoin se até mesmo uma grande figura experiente, considerada especialista, pode cometer erros? Será que esse desenvolvedor é um risco para o Bitcoin em si por ser uma figura importante dentro da implementação de referência do protocolo, a Bitcoin Core? Ocorrência com o desenvolvedor Luke Dashjr https://twitter.com/LukeDashjr/status/1609613748364509184 Tweets sobre o ocorrido: https://twitter.com/bitdov/status/1609727946947952640 https://twitter.com/bitdov/status/1609983860338573312 https://twitter.com/bitdov/status/1609730870369456131 Vídeo recente sobre porque sacar o Bitcoin da corretora https://youtu.be/7fsWG0VIXAc Vídeo Peter Safesrc https://www.youtube.com/watch?v=2uLlUIahr1E Playlist Hardwallet Bitcoin Faça você mesmo https://www.youtube.com/playlist?list=PLgcVYwONyxmjTL7yTCLcpUqiTyyLKm83s Playlist Criação segura de seed BIP39 https://www.youtube.com/playlist?list=PLgcVYwONyxmiz-CzJmqQHKyJm8-t6Tp8p Gravado no bloco 770145 ________________ APOIE O CANAL https://bitcoinheiros.com/apoie/ ⚡ln@pay.bitcoinheiros.com Loja dos Bitcoinheiros https://loja.bitcoinheiros.com/ SIGA OS BITCOINHEIROS: Site: https://www.bitcoinheiros.com Youtube: https://www.youtube.com/bitcoinheiros Twitter: https://www.twitter.com/bitcoinheiros Allan - https://www.twitter.com/allanraicher Dov - https://twitter.com/bitdov Becas - https://twitter.com/bksbk6 Ivan - https://twitter.com/bitofsilence Instagram: https://www.instagram.com/bitcoinheiros Facebook: https://www.fb.com/bitcoinheiros Podcast: https://anchor.fm/bitcoinheiros COMO GUARDAR SEUS BITCOINS? Bitcoinheiros recomendam o uso de carteiras Multisig com Hardware Wallets de diferentes fabricantes ou próprias. Para ver as carteiras de hardware que recomendamos, acesse https://www.bitcoinheiros.com/carteiras Veja os descontos e clique nos links de afiliados para ajudar o canal Por exemplo, para a COLDCARD - https://store.coinkite.com/promo/bitcoinheiros Com o código "bitcoinheiros" você ganha 5% de desconto na ColdCard Playlist "Canivete Suíço Bitcoinheiro" https://www.youtube.com/playlist?list=PLgcVYwONyxmg-KH5bwzMU4sdyMbVMPqwb Playlist "Carteiras Multisig de Bitcoin" https://www.youtube.com/playlist?list=PLgcVYwONyxmi74PiIUSnGie --- Send in a voice message: https://anchor.fm/bitcoinheiros/message

JCO PO author Dr. Mark Yarchoan, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, shares research on the four distinct subsets of biliary tract cancers (BTCs) and their varying immune responses and mutations. Dr. Naqash and Dr. Yarchoan discuss the article's study of intrahepatic cholangiocarcinoma [IHC], extrahepatic cholangiocarcinoma, and gallbladder cancer. Click here to read the article! Dr. Naqash: Welcome to ASCO's JCO Precision Oncology Conversations where we bring you the highlights and overview of precision oncology. Episodes will feature engaging conversations with authors of clinically relevant and highly impactful and significant JCO PO articles. These articles can be accessed at ascopubs.org/journals/po. Hi, I am Dr. Rafeh Naqash, Assistant Professor of Medicine at Oklahoma University Stephenson Cancer Center, where I focus on Phase I clinical trials and lung cancer. You're listening to JCO Precision Oncology Conversations podcast. Today, I will be talking with Dr. Mark Yarchoan about his recent paper, Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. Dr. Yarchoan is an Associate Professor of Medicine in the GI Medical Oncology branch at the Johns Hopkins, Sydney Kimmel Comprehensive Cancer Center. Full disclosure for our guests will be linked in the show notes and can be found on the article's publication page. Dr. Yarchoan, thank you so much for joining us today. Dr. Yarchoan: Thank you for having me. Dr. Naqash: For the sake of our listeners, Mark, could you tell us about your professional background and your research interests? Dr. Yarchoan: Sure. I'm a medical oncologist by training focused on hepatobiliary malignancies at the Johns Hopkins Hospital, a co-director of Liver Multidisciplinary Clinic, and I'm interested in novel immunotherapeutic approaches to treating liver cancers. Dr. Naqash: That is definitely an unmet need, which we're going to talk about more as we discuss your paper. Again, for the sake of our listeners, before we take a deeper dive into the published paper, could you provide us a one-minute overview of the main findings from your manuscript that was published in JCO Precision Oncology? Dr. Yarchoan: Absolutely. So, we looked at the molecular subtypes of cholangiocarcinoma. So, there are essentially two common forms of liver cancer. There's hepatocellular carcinoma and biliary tract cancers, also sometimes called cholangiocarcinomas. Cholangiocarcinomas are the rarer of the two types of liver cancer and we know that cholangiocarcinoma's not really one cancer, it's a number of different cancers that all anatomically start within the bile ducts of the liver. And what we did working with a number of different collaborators and then also, with Tempus, which is a major molecular profiling company, is we looked at the landscape of mutations that occur in cholangiocarcinoma, and then tried to correlate these mutations with features of the tumor immune microenvironment using RNA data from the same tumors. Dr. Naqash: Thank you so much. So, again, being a thoracic oncologist myself, we have a lot of excitement associated with immune checkpoint alone or immune checkpoint in combination with chemotherapy, similar to what has been seen in some of the upper GI cancers in the last couple of years. Now, before you started this paper or this work with Tempus, what was known about the landscape of biliary tract cancers and what have been the standard approaches of management for advanced biliary tract cancers? Dr. Yarchoan: You know, many of us who treat biliary tract cancers have joked for years that we treat the lung cancer of the GI cancer world because so many of these cancers have actionable molecular alterations. I think that's something that has been known for a long time. Over the last couple of years, for the first time, we have multiple drug approvals in cholangiocarcinoma for molecularly defined subsets of disease. So, for example, we have now inhibitors of FGFR2 that have been approved for FGFR2 fusions or rearrangements. We have an IDH1 inhibitor approved for cholangiocarcinoma. There are some tumor agnostic approvals like for BRAF and NTRK, all of which we do occasionally find in biliary tract cancer. So, you know I think it's been known for a long time that looking for molecular alterations is fruitful in cholangiocarcinoma. You often find these things and these cancers often respond to these agents. I think what is unique here is we've taken this knowledge and first of all, this is the largest series of biliary tract cancer that has ever been profiled to our knowledge, and other profiling efforts have been international. But we know that biliary tract cancer in Southeast Asia can sometimes be different from what we see here in the U.S. because there, those cancers are often caused by liver flukes, which we don't tend to see as much in the U.S. So, the genetics can be somewhat different. And finally, I think what is unique about our paper is that we have actually correlated these molecular differences, these molecular drivers of cholangiocarcinoma. And we've correlated these drivers with the RNA from the same tumor to really understand when you have a tumor that is for example, FGFR2 fusion or rearrangement, what is typically found in the immune microenvironment from that same tumor. Dr. Naqash: Thank you for that explanation. Now, going back to why biliary tract cancer's potentially not as responsive to immune checkpoint inhibitors as some of the other GI-based tumors — pancreatic cancer, as you very well know, has a certain tumor microenvironment associated with presence of fibroblasts and other immunosuppressive macrophages that result in lack of response to immunotherapy-based combinations. What is unique in biliary tract cancers, as you've nicely explained in the discussion or your introduction, that based on Keynote-158, the response rates have generally been in the range of 2 to 10%. So, what is unique here that results in tumors being not so responsive to immunotherapy-based combinations? Dr. Yarchoan: Yeah, biliary tract cancers tend to be fairly immune resistant cancers. As you mentioned, the response rate to single agent anti PD-1 immunotherapy is probably in a range of about 5 to 10% in most studies. We do have new data now from the TOPAZ-1 study, this is a randomized first line study of Gemcitabine Platinum with or without durvalumab, which is a PDL1 inhibitor where the addition of durvalumab did modestly improve survival. So, there is some activity for immunotherapy, but it's quite low as you mentioned. And again, I think that we're still learning why this is, but cholangiocarcinoma tends to have, number one, a very low tumor mutation burden. So, the total number of mutations, which is a surrogate for the number of neoantigens that the immune system can see tends to be low. But also, when we look at the immune microenvironment at these cancers, we tend to find relatively low numbers of effector T cells in the microenvironment, which are an anti-tumor subset. We tend to find high numbers of immunosuppressive cell types, M2 macrophages and T regulatory cells. And these tumors also tend to have a lot of stroma which can impede the immune system coming in. So, the two major accesses that can determine immune sensitivity, the mutational burden in the immune cells, and the microenvironment, both point to an immune suppressed tumor type. Dr. Naqash:  Totally agree. And I think that's why findings that you describe in this paper have a lot of relevance to precision medicine and how we can approach biliary tract cancers, not just anatomically but also from a molecular standpoint. Going back to lung cancer analogy, small cell lung cancer until a few years back was considered one entity and now, it is three to four different entities based on some transcriptional factors which determine how patients respond. And I believe there is something similar going on here like you described. So, now taking a deeper dive into the paper, you did mutational signature analysis clustering, and then you also assessed RNA. What would some of the mutation-specific findings associated with whether tumors were intrahepatic or extrahepatic gallbladder in this manuscript? Dr. Yarchoan: Sure. So, we, as you mentioned, did some cluster analysis looking at the driver mutations in cholangiocarcinoma. And what we found were essentially, there appeared to be four distinct subsets of these cancers. One subset which has been reported in other similar cluster analyses, including an international cluster analysis; one subset really appears to be driven by FGFR2 fusions or rearrangements and is entirely an intrahepatic cholangiocarcinoma subset. And we found that this subset tended to have the lowest immune infiltration of any of the four subsets that we looked at. A second subset, which we called mutational cluster three, was both intrahepatic and extrahepatic disease. And the most common mutation was really in CDKN2A or N2B. The second cluster that we looked at, clusters 1, 2, 3, 4 — I think is one of the most interesting clusters. And this is a cluster that was enriched for genes that seemed to alter the epigenome of the tumor. So, for example, IDH1 mutations, which we know result in an oncometabolite 2HG were common in the subset also ARID1A and PBRM1 were common. And then finally, the largest subset of all were the tumors that had frequent mutations in KRAS, TP53 among other mutations. We found that this was the most inflamed cluster, had the highest PD-L1 expression, slightly enriched in the extrahepatic subset versus intrahepatic subset. Dr. Naqash: Definitely interesting findings based on the cluster analysis and the mutations in each cluster. Going to cluster one where you have found that TP53, ATM, et cetera, mutations are commonly altered genes, are you suggesting based on some of this work that the immune inflamed tumor microenvironment could potentially be linked to TP53, which is cell cycle checkpoint, which when altered could result in higher DNA damage similarly with ATM being in the DNA damage pathway. Could that be a potential explanation for why these alterations are resulting in a hot tumor immune microenvironment? Dr. Yarchoan: Certainly, could be. You know, obviously, we can't prove that. This was correlative, but I think that would certainly explain what we found. Dr. Naqash: And again, going back to cluster four with FGFR2 and BAP1 alterations, which had the lowest PD-L1 and lowest immune microenvironment inflammatory signature, is that potentially a cluster that you think would most commonly benefit from targeted therapies rather than immune checkpoint-based therapies? Dr. Yarchoan: That's our hypothesis here. This was a subgroup that appeared to be non-inflamed, had a low mutational burden. Genomically, I would call this a stupid cancer in the sense that there's a very powerful driver mutation and not a whole lot else going on here. It seems like the sort of tumor that may benefit from targeted therapy. I think what we don't know, and one of the questions that immediately comes out of this work is, is FGFR2 itself immunosuppressive and that's why we don't find a lot of immune cells. And if so, it raises the question whether these sort of cluster four tumors would benefit from a combination approach of targeted therapy plus immunotherapy. And so, I think that's an open question, something that we hope to look into. Dr. Naqash: Definitely, leads to potential subsequent work in this field to expand more on these findings. Now, going back to some of the other important findings in your paper, you described actionable biomarkers in the biliary tract cancers based on proven trials with specific therapies. One of the questions that I had was you take TMB ≥10 as a potentially actionable biomarker. Is that true for biliary tract cancers? Because there's data from different groups showing that different TMB cutoffs have different meaning for different types of tumors. So, is 10 a cutoff where you are reasonably comfortable in saying that potentially, single agent immunotherapy may work and TMB here is predictive of outcomes, or do you think a higher TMB is probably more relevant in these cancers that are generally not immune responsive? Dr. Yarchoan: Yeah, the approval for pembrolizumab in high TMB tumors has been controversial. I think probably more controversial than it should be. But Keynote-158, which was sort of a prospectively analyzed study of pembrolizumab and multiple tumor histologies, actually included biliary tract cancers. And the response rate in that study for biliary tract cancer in the TMB high group again, small numbers of patients but, was consistent with pembrolizumab being very active. I have to say in my own clinic, I've had some absolutely spectacular responses for high TMB biliary tract cancer, and so I tend to believe the data. I've actually had complete responses. I've had patients downstage to surgery who went on single agent anti PD-1. So, I think this is an important group of patients and I think it is a group that we shouldn't miss for biliary tract cancer. Dr. Naqash: Definitely agree with you. All of us strive as medical oncologists to get some of those complete responses that don't come often very commonly or easily. But it's always nice to see those responses and individuals especially with these biomarker-specific tumors with high TMB or high PD-L1. Now, other findings from your paper, you describe mutual exclusivity of two mutations in a certain subgroup, which was TP53 and BAP1. Could you explain the clinical relevance or the molecular significance of these mutually exclusive mutations and what they might mean in the context of this tumor? Dr. Yarchoan:The short answer is these were clearly in different immune subsets and different molecular subsets. Again, the TP53 belonged to what we called cluster one. Usually, went with KRAS, was more common in extrahepatic disease. The BAP1 mutations tended to go along with FGFR2 fusions or rearrangements, was intrahepatic. But exactly why these were mutually exclusive, why was it not evolutionarily advantageous for tumors to have both of these things at once? You know, I think remains an unanswered question. There's certainly a hypothesis for why the tumor wouldn't need both, but I don't know. Dr. Naqash:  And you also looked at PD-L1 and tumor mutational burden across the biliary tract tumor subtypes. Could you tell us more about some of those findings? Dr. Yarchoan: Yeah, for sure. I mean, I think our cluster one, which again was the most inflamed cluster, had more KRAS, more TP53 — not surprisingly seemed to have the most immune infiltration, the highest PD-L1 expression in a trend towards a higher tumor mutation burden as well. Not totally surprising. I don't want to over-interpret that finding though because we've looked now at the prospective data from TOPAZ-1 where patients got GemCis with or without durvalumab. As a matter of fact, PD-L1 was not a very strong predictor for durvalumab benefit in that study. So, I wouldn't over-interpret the trend towards higher PD-L1 expression in that subset. It may not be very clinically actionable. Dr. Naqash:  Sure. Now, another finding is the TMB comparisons across the biliary tract cancer subtypes. And to me, it seemed like the TMB, median TMB, was slightly different but not significantly different that may not necessarily have a huge clinical relevance. Do you agree with that? What are your thoughts on that side? Dr. Yarchoan: We're in an era now where we just get TMB at an individual patient level. So, I don't think we're going to be relying on cluster analysis to figure out a patient's TMB. So, I don't think it's necessarily clinically actionable. I do think there were some findings here that are interesting from a research perspective. For example, ARID1A was associated with a higher tumor mutation burden; something that's been reported in other tumor types and that's certainly interesting and something that should be followed up on, I think, from a research standpoint. Dr. Naqash: Excellent. Now, last figure that I came across, which was again, very interesting, was that you analyze association between all the different mutations and different immune gene signatures. And it seemed based on the figure that TP53, again, stood out when you correlated with PD-L1 or CDA T cell or other immune inflammatory gene signatures. Is there something going on with TP53 here that you think is potentially relevant co-mutation in this tumor, which could lead to some novel therapeutic combination approaches? Dr. Yarchoan: Yeah, I don't want to over-interpret our work, but I agree, it's very interesting and this is a topic that is being investigated in many tumor types because TP53 is something that appears in many tumors including the ones that you treat. So, I think this is particularly relevant because we have a bunch of TP53 targeted therapies coming down the pike. How those will modulate the tumor immune microenvironment is an interesting topic. So, maybe just for sake of discussion, are you finding the same thing in lung cancer and what's the thought process in lung cancer now? Dr. Naqash:  Yes, again, very interesting question. So, we actually had some data last year that we presented in the context of lung cancer in STK11, which is again, commonly found in pancreatic and biliary cancers also. And we saw TP53 co-mutated tumors had a very high immune inflammatory gene signature with all the different aspects of immune infiltration or Interferon gamma upregulation (IFN-γ). So, likely, our assessment was that this was potentially linked to the cell cycle aspect and higher neoantigens for DNA damage. So, something common probably going on here in this tumor type as well as you mentioned. So, one of the other things that I came across, which is interesting and I've come across a patient actually a few years back with cholangiocarcinoma, but that was associated with a liver fluke. The tumors that you assess using the Tempus database obviously, were from North America and did not have Asian patients. And from my understanding, TOPAZ-1 did include a decent number of patients from Asia. So, have you looked at or is there a potential reason to believe that liver fluke-associated tumors may have a higher inflammatory signature or has there been any data in comparing liver fluke versus non-liver fluke-associated biliary tract tumors to see what could be the genomic transcriptomic differences there? Dr. Yarchoan: Yeah, as you mentioned, our study was purely for North American patients. It's not that there were no Asian patients. There certainly were Asian patients, including patients who may have been born in Southeast Asia but immigrated here. There have been other analyses of the molecular landscape of biliary tract cancer that were international and included more patients from Asia, including a paper in Cancer Discovery a couple of years ago that I think is worth reading. Overall, I think there is some data that this subgroup of patients may have a unique tumor immune microenvironment and unique mutational landscape. We tend to find more for two in these patients. They do tend to be, I think, a little more inflamed, have more PD-L1 expression. Interestingly, in the TOPAZ-1 study, which again, was the prospective study of durvalumab, there appeared to be more benefit to durvalumab in patients in Asia than patients in the West. And it does raise the question whether that could be mediated in part by this liver fluke ideology. So, again, certainly not a settled question, but something interesting that should be followed up on. Dr. Naqash:Definitely interesting. I would again like to thank you Dr. Yarchoan and your team for this excellent work and sharing all your thoughts with us today, and giving us more insights into biliary tract cancers. On behalf of JCO PO, I'd like to thank you for considering JCO PO as the final destination for this interesting work, and hopefully, you consider JCO PO for future work as well. Dr. Yarchoan: Well, thank you for highlighting our work and for the opportunity to publish, and thanks for this discussion. Dr. Naqash: Absolutely. It's been a pleasure talking to you today, and hopefully, our audience will find this conversation equally intriguing and interesting. Thank you for listening to JCO Precision Oncology Conversations. You can find all our shows, including this one at asco.org/podcasts or wherever you get your podcasts. To stay up to date, be sure to follow and share JCO PO content on Twitter. Our Twitter handle is @JCOPO_ASCO. All JCO PO articles and series can be found at ascopubs.org/journals/po.   Voiceover:  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Disclosures Mark Yarchoan  Consulting or Advisory Role: Eisai, Exelixis, AstraZeneca, Genentech/Roche, Replimune, Hepion Pharmaceuticals  Research Funding: Bristol Myers Squibb (Inst), Merck (Inst), Exelixis (Inst), Incyte (Inst)   Guest Bio Dr. Mark Yarchoan, MD, is a medical oncologist focused on hepatobiliary malignancies at the Johns Hopkins Hospital and co-director of Liver Multidisciplinary Clinic.

Las últimas noticias Bitcoin hoy y las mejores criptonoticias en Bit2Me Crypto News: 📈 34.000 BTCs abandonan los intercambios cripto. 💸 Transit Swap pierde 21 millones de dólares en un exploit. 🌍 Terra podría dejar una regulación similar a la Libra de Facebook. Para ésta y otras noticias, puedes ver el noticiario completo de hoy, pincha aquí 👉 https://youtu.be/Gqoh7jUysS4! 🚀 Suscríbete a nuestro Canal: https://www.youtube.com/channel/UCBiA... #Criptonoticias #Bitcoin #Blockchain #Criptomonedas 🎁 ¡Has descubierto un regalo! Si estás aquí, aprendiendo, te mereces nuestro regalo especial: Regístrate en Bit2Me con este enlace y en tu primera compra de 100€ o más te regalaremos 5€: https://up.bit2me.com/ytnewsreg ¡La revolución la creamos entre todos! 📲¡Descárgate la APP de Bit2Me! https://up.bit2me.com/appyt Nuestra web: https://up.bit2me.com/2a 👉 Síguenos en las redes sociales: ⭕️ Facebook: https://www.facebook.com/bit2me ⭕️ Instagram: https://www.instagram.com/bit2me ⭕️ Twitch: https://www.twitch.tv/bit2me ⭕️TikTok: https://www.tiktok.com/@bit2me ⭕️ Linkedin: https://www.linkedin.com/company/9243641 ⭕️ Twitter: https://twitter.com/bit2me ⭕️ Telegram: https://t.me/Bit2Me_ES ⭕️ Lbry (Odysee): https://odysee.com/@bit2me:c ⭕️ Spotify: https://open.spotify.com/show/1Tj4kyX... ⭕️ iVoox: https://www.ivoox.com/podcast-bit2me-... y por supuesto, dale a la campanita para activar las notificaciones 👈 ✍🏻 ¡Apunta! Conoce todos nuestros servicios: ⭕️ Wallet: https://up.bit2me.com/2e ⭕️ Tikebit (compra criptomonedas en tiendas físicas): https://www.tikebit.com/ ⭕️ Academy: https://up.bit2me.com/2g ⭕️ Crypto News: https://up.bit2me.com/2h

This week we welcomed long-time DMB collaborator Sam Erickson to the podcast! Sam was an integral part in documenting the band's early years as a photographer and videographer. We talk about everything from their 1996 European tour with Bob Dylan, his holy grail BTCS documentary, the incredible Dave & Tim Radio City DVD, the other musical beginnings and careers he helped document (John Mayer, P Diddy, My Morning Jacket, Trey Anastasio and more) and what's next for him. Big thanks to Sam for joining us - enjoy!

Featuring a slide presentation and related discussion from Professor Juan Valle, including the following topics: Management of biliary tract cancers (BTCs) with targetable mutations (0:00) Management of BTCs without targetable mutations (13:59) Novel targets and treatments for cholangiocarcinoma and other BTCs (20:19) CME information and select publications

Featuring an interview with Professor Juan Valle, including the following topics: Immunotherapy for patients with biliary tract cancers (BTCs) (0:00) Etiology and presentation of and recent advances in the management of cholangiocarcinoma (4:18) Targeting FGFR alterations in cholangiocarcinoma and other BTCs (12:47) Spectrum and management of toxicities associated with FGFR inhibitors (19:33) Targeting driver mutations beyond FGFR (28:16) Case: A man in his early 60s with intrahepatic cholangiocarcinoma, an FGFR2 fusion and an IDH1 R132C mutation (35:53) Case: A woman in her early 60s with intrahepatic cholangiocarcinoma and an IDH1 mutation that did not respond to third-line ivosidenib (41:49) Case: A woman in her early 60s with gallbladder cancer who received first-line chemotherapy with pembrolizumab (46:15) CME information and select publications

The finance police are coming for the digital asset industry -- but are they moving fast enough, or will the sector swiftly improve its compliance capabilities to get out ahead of the regulators? Where does this leave investors? Financial News' Trista Kelley, Jeremy Chan speak to Charles Allen, Chairman and CEO of BTCS, for the inside track. 

What if I told you that NFTs might become the future of voting? Listen in as I speak with Charles Allen, Chairman and CEO of BTCS, about cryptocurrencies, NFTs, blockchain and why we should care. Charles explains the different types and why one would invest in any of them. He will also take us through the various use cases. Finally, he addresses some of your questions and concerns around volatility. NOTE: Bitcoin and other cryptocurrencies are a very speculativeinvestment and involves a high degree of risk. Investors must have thefinancial ability, sophistication/experience and willingness to bear the risksof an investment, and a potential total loss of their investment.Note to All Readers: The information presented andopinions expressed are solely the views of the podcast host commentator andtheir guest speaker(s).  AllianceBernstein L.P. or its affiliates makes norepresentations or warranties concerning the accuracy of any data. There is noguarantee that any projection, forecast or opinion in this material will berealized. Past performance does not guarantee future results. The viewsexpressed here may change at any time after the date of this podcast. Thispodcast is for informational purposes only and does not constitute investmentadvice. AllianceBernstein L.P. does not provide tax, legal or accountingadvice. It does not take an investor's personal investment objectives orfinancial situation into account; investors should discuss their individualcircumstances with appropriate professionals before making any decisions. Thisinformation should not be construed as sales or marketing material or an offeror solicitation for the purchase or sale of any financial instrument, productor service sponsored by AllianceBernstein or its affiliates.The [A/B] logo is a registered service mark ofAllianceBernstein, and AllianceBernstein® is a registered service mark, used bypermission of the owner, AllianceBernstein L.P.

Narcelio, Otto e Ricardo vem para contar como solucionaram o enigma do livro "Satoshi", do Rafael Boskovic. Detalhes sobre o livro e o enigma: https://www.rafaelboskovic.com.br/satoshi MINUTAGEM 00:00 Sala de espera 03:20 Vídeo "Cheque os seus privilégios financeiros" 08:13 Introdução 09:42 Apresentação dos convidados Rafael Boskovic, Narcélio, Otto, Arab e Ricardo 11:00 O enigma de 200 BTCs ainda está valendo? 14:21 Diversos artistas criaram enigmas para divulgar o Bitcoin 16:08 O enigma do livro "Satoshi" 17:18 Por que Rafael criou o enigma e qual foi sua inspiração? 19:06 Como começou a ser criado o enigma do livro "Satoshi"? 19:44 Como os envolvidos começaram a procurar nomes e resolver o enigma 24:50 O filtro de referências e a formação da equipe para encontrar a seed 28:27 Referências geográficas e a quantidade de tempo usado para testar os nomes 38:00 Como funcionava o programa para achar a seed e o algoritmo da Warp Wallet 44:39 A referência sobre Bill Gates que não acreditaram ser verdadeira 45:35 A ferramenta que utilizaram para separar as informações do livro 47:25 "E se alguém criar uma carteira igual a minha?" 49:07 A descoberta do penúltimo nome e a inesperada ajuda de um perfil suspeito do Twitter 57:53 O pressentimento de Narcélio sobre o último nome e a sorte em acertá-lo 01:00:53 Existe diferenças entre o enigma do livro comparado com os de quadros? 01:04:57 Promoção inédita do livro "Satoshi", não perca! ________________ APOIE O CANAL https://bitcoinheiros.com/apoie/ ⚡ln@pay.bitcoinheiros.com Loja dos Bitcoinheiros https://loja.bitcoinheiros.com/ SIGA OS BITCOINHEIROS: Site: https://www.bitcoinheiros.com Youtube: https://www.youtube.com/bitcoinheiros Twitter: https://www.twitter.com/bitcoinheiros Allan - https://www.twitter.com/allanraicher Dov - https://twitter.com/bitdov Becas - https://twitter.com/bksbk6 Ivan - https://twitter.com/bitofsilence Instagram: https://www.instagram.com/bitcoinheiros Facebook: https://www.fb.com/bitcoinheiros Podcast: https://anchor.fm/bitcoinheiros APOIE O CANAL: - Dê uma gorjeta em Bitcoin: https://bitcoinheiros.com/apoie/ - Inscreva-se no canal - Deixe seu comentário no vídeo - Dê um like no vídeo - Compartilhe o vídeo e o canal com amigos e familiares na sua rede social - Envie um email com seu comentário e sugestões: bitcoinheiros@protonmail.com COMO GUARDAR SEUS BITCOINS? Bitcoinheiros recomendam o uso de carteiras Multisig com Hardware Wallets de diferentes fabricantes. Busque por "canivete bitcoinheiro" em nosso canal para saber mais. - COLDCARD - https://store.coinkite.com/promo/bitcoinheiros (use o código bitcoinheiros para ganhar 5% de desconto) - TREZOR E BITBOX02 PARA RESIDENTES NO BRASIL E AMÉRICA D --- Send in a voice message: https://anchor.fm/bitcoinheiros/message

#Bitcoin #ElSalvador #CardanoI'd like to welcome everyone to my new PODCASTDave's Daily Crypto TakeIn this channel I will be providing you with news on a daily basis about cryptocurrency, bitcoin, blockchain, FIAT. My main purpose is to share UNBIASED news and updates. Ultimately I learn and hopefully you learn while I go on this journey.ARTICLES used in today's video:https://ambcrypto.com/8-or-58-3rd-or-7th-what-the-experts-say-about-where-cardano-will-go/$8 or $58? 3rd or 7th? – What the ‘experts' say about where Cardano will goIn 2021, Cardano was the third-biggest crypto by market cap, breathing down Ethereum's neck. However, 2022 saw it in seventh place. To that end, Finder's panel of fintech experts came together to predict ADA's future price performance. The final estimate was well worth a read.A full deck of CardanoTo make a long story short, the target is for ADA to hit $2.79 by the end of 2022. It might not remind investors of Solana's dazzling rise to $100 and beyond, but is still a 168% rally.https://www.coindesk.com/learn/crypto-capital-gains-and-tax-rates-2022/Crypto Capital Gains and Tax Rates 2022According to an IRS notice published in 2014, cryptocurrencies including NFTs are classified as “property” meaning they are liable to a capital gains tax similar to stocks or “real” property.A capital gain occurs if you sell a crypto for more than your initial investment. For instance, if you buy one bitcoin for $20,000 and sell it for $50,000, you have made $30,000 of taxable gains. In other words, if you make profit from the sale of a crypto or a non-fungible token (NFT), you trigger a taxable event in the eyes of the IRS.https://ambcrypto.com/whales-are-counting-sheep-and-bitcoin-may-finally-be-ready-for/Whales are counting sheep and Bitcoin may finally be ready for…Will it or won't it? That is the question many crypto-investors have as they wait with bated breath for Bitcoin to either cross $40,000 again or drop back to its $35,000 lows. However, not all investors are equal and there are some factors to keep in mind.Whales are counting sheep?Bitcoin whales with a balance of between 100 and 100,000 BTCs have not significantly risen or fallen this month. Curiously, this was in spite of drastic price changes.In fact, one crypto-analyst suggested that the whales might be waiting for a sale so as to snap up the king coin at an even lower price. In light of Bitcoin falling below $34,000 in late January, this might not be a far-fetched idea.https://bitcoinist.com/biden-to-issue-crypto-executive-order/Biden To Issue Crypto Executive Order This Week – Bad News For The US Dollar?United States President Joe Biden is poised to release a crypto executive order this week, an administration official with knowledge of the matter disclosed.The EO will direct government agencies to conduct detailed examinations of various areas of the crypto asset landscape in order to develop an extensive regulatory framework.https://cointelegraph.com/news/pro-bitcoin-president-of-el-salvador-to-offer-citizenship-for-foreign-investorsPro-Bitcoin president of El Salvador to offer citizenship for foreign investorsSalvadoran President Nayib Bukele wants to offer citizenship to those who invest in the small Central American nation.President Bukele took to Twitter to inform the crypto community on Sunday that he was sending a list of 52 legal reforms to Congress. Among the most notable proposals, Bukele called for the removal of red tape, reducing bureaucracy, creating tax incentives and, most importantly, offering citizenships to foreigners looking to invest in the nation.https://alternative.me/crypto/fear-and-greed-index/https://coinmarketcap.com/Please subscribe, like, and share so that more and more people can view this content.DISCLAIMER: I will never give any financial advice. And my channel is not considered official Financial Advice. Please do your research before purchasing any cryptocurrency.Thank you very much DaveSupport this podcast at — https://redcircle.com/daves-daily-crypto-take/donations

BitNada - Seu jornal diário sobre Mercado, Bitcoin e Criptomoedas Sempre às 07h50min horário de Brasília. De Segunda a sexta.

Andrew Steinwold is the managing partner at Sfermion, one of the leading NFT funds. He's an investor in OpenSea, Art Blocks and many other NFT projects. In this project, we discuss the growing NFT space, evaluating new projects, gaming and how to think about NFTs vs. NFT infrastructure. ======================= Today's episode is sponsored by Abra. Based in California and backed by top VC firms, Abra is an all-in-one simple, secure app that allows you to trade over 110 cryptocurrencies, get 0% interest loans using your crypto as collateral and earn interest with up to 14% APY on stablecoins and 8.15% APY on Bitcoin. Join nearly 2 million users by downloading Abra from the Google Play or Apple App store. If you download the app today, you will get $15 in free crypto once you fund your account. You came, you invested — now conquer. ======================= Unstoppable Domains is THE #1 provider of NFT domains. These aren't traditional domains, these are domains with superpowers. With your unique NFT domain such as pomp dot crypto or pomp dot nft, you can replace your long complex wallet addresses, verify ownership of your NFTs and join the 10's of thousands of people who are now using their NFT domain as their Twitter and Discord usernames. Go to unstoppabledomains.com and get YourName dot crypto, dot x, dot nft or a range of other endings for as low as $5 and never worry about gas or renewal fees because with Unstoppable Domains you pay once and own forever! ======================= Nasdaq-listed BTCS was the first US-public company to secure today's top layer one protocols. Recently, BTCS launched the beta version of its digital asset analytics dashboard! From across multiple exchanges, the BTCS Data Analytics Dashboard lets you evaluate your entire portfolio's performance with plans to add year-end reports and yield earning on your crypto through linking to staking pools. Test out the BTCS Data Analytics Dashboard today at BTCS.com. =======================

Darius Dale is the Founder & CEO of 42 Macro, the leading macro risk manager adviser. In this conversation, we discuss the macro economy, what's happening in the financial markets, how Darius is looking at various metrics, and what you should be considering as you're investing your capital. Darius joins us every Thursday on "The Best Business Show." To see the video with the corresponding charts that Darius references throughout the interview, go to "The Best Business Show: LIVE" YouTube Channel. ======================= Today's episode is sponsored by Abra. Based in California and backed by top VC firms, Abra is an all-in-one simple, secure app that allows you to trade over 110 cryptocurrencies, get 0% interest loans using your crypto as collateral and earn interest with up to 14% APY on stablecoins and 8.15% APY on Bitcoin. Join nearly 2 million users by downloading Abra from the Google Play or Apple App store. If you download the app today, you will get $15 in free crypto once you fund your account. You came, you invested — now conquer. ======================= Unstoppable Domains is THE #1 provider of NFT domains. These aren't traditional domains, these are domains with superpowers. With your unique NFT domain such as pomp dot crypto or pomp dot nft, you can replace your long complex wallet addresses, verify ownership of your NFTs and join the 10's of thousands of people who are now using their NFT domain as their Twitter and Discord usernames. Go to unstoppabledomains.com and get YourName dot crypto, dot x, dot nft or a range of other endings for as low as $5 and never worry about gas or renewal fees because with Unstoppable Domains you pay once and own forever! ======================= Nasdaq-listed BTCS was the first US-public company to secure today's top layer one protocols. Recently, BTCS launched the beta version of its digital asset analytics dashboard! From across multiple exchanges, the BTCS Data Analytics Dashboard lets you evaluate your entire portfolio's performance with plans to add year-end reports and yield earning on your crypto through linking to staking pools. Test out the BTCS Data Analytics Dashboard today at BTCS.com. =======================

Ben Miller is the Co-Founder & CEO of Fundrise, America's largest real estate investment platform. In this conversations, we discuss real estate market, interest rates, and the different trends for investors in the real estate investment asset class since the start of the global pandemic. ======================= Today's episode is sponsored by Abra. Based in California and backed by top VC firms, Abra is an all-in-one simple, secure app that allows you to trade over 110 cryptocurrencies, get 0% interest loans using your crypto as collateral and earn interest with up to 14% APY on stablecoins and 8.15% APY on Bitcoin. Join nearly 2 million users by downloading Abra from the Google Play or Apple App store. If you download the app today, you will get $15 in free crypto once you fund your account. You came, you invested — now conquer. ======================= Unstoppable Domains is THE #1 provider of NFT domains. These aren't traditional domains, these are domains with superpowers. With your unique NFT domain such as pomp dot crypto or pomp dot nft, you can replace your long complex wallet addresses, verify ownership of your NFTs and join the 10's of thousands of people who are now using their NFT domain as their Twitter and Discord usernames. Go to unstoppabledomains.com and get YourName dot crypto, dot x, dot nft or a range of other endings for as low as $5 and never worry about gas or renewal fees because with Unstoppable Domains you pay once and own forever! ======================= Nasdaq-listed BTCS was the first US-public company to secure today's top layer one protocols. Recently, BTCS launched the beta version of its digital asset analytics dashboard! From across multiple exchanges, the BTCS Data Analytics Dashboard lets you evaluate your entire portfolio's performance with plans to add year-end reports and yield earning on your crypto through linking to staking pools. Test out the BTCS Data Analytics Dashboard today at BTCS.com. =======================

Crypto Corner Podcast 749: Stocks discussed: (NasdaqCM: BTCS) (NasdaqCM: RIOT) (NasdaqCM: CLSK)

Crypto Corner Podcast 749: Stocks discussed: (NasdaqCM: BTCS) (NasdaqCM: RIOT) (NasdaqCM: CLSK)

Crypto Corner Podcast 749: Stocks discussed: (NasdaqCM: BTCS) (NasdaqCM: RIOT) (NasdaqCM: CLSK)

Oh I think you're going to see more of this:BTCS Inc. (Nasdaq: BTCS) ("BTCS" or the "Company"), a blockchain technology-focused company, has announced... see more of this arguedthe little form are gapscustody obligationscapital requirements tried it in 2019 I half-jokingly arguedmedallions tradedvery funny enforcement lawsuitthe SEC’s complaintMedallion apparently disagreesannual report for 2017 discussed lothedge fund managers mortgage firms ETF managers but it is funnycut back traditional lendingChinese Tech Companies Fully Autonomous Tractorvalued at $13.3 billionBored Ape Yacht Club NFT HypeDabble in CryptoBlackBerry Die-Hardsbrilliant with moneyanti-semitic email rantretires from selling fartssubscribe at this linkhereForm 8-Kpage F-3 here

Bianca Cotton is the Founder of Behind The Confident Smile. She began the BTCS movement to encourage women from diverse backgrounds to hope again, be inspired to live their best lives and be healed from past hurts. Today she shares the origin story behind this mission. Stay connected with her by visiting behindtheconfidentsmile.com or follow her on Instagram. @behindtheconfidentsmile Find out more about her course on releasing fear by visiting blackgirlswithpurpose.org/activate - an online learning platform for women of faith in business. --- Send in a voice message: https://anchor.fm/painandpurpose/message Support this podcast: https://anchor.fm/painandpurpose/support